NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ME Stock Alerts $0.48 -0.01 (-2.03%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5250-Day Range$0.36▼$0.5752-Week Range$0.35▼$2.21Volume2.10 million shsAverage Volume6.82 million shsMarket Capitalization$233.11 millionP/E RatioN/ADividend YieldN/APrice Target$0.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get 23andMe alerts: Email Address 23andMe MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside2.6% Downside$0.47 Price TargetShort InterestHealthy10.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 7 Articles This WeekInsider TradingSelling Shares$97,528 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.72 out of 5 starsMedical Sector806th out of 905 stocksPharmaceutical Preparations Industry387th out of 422 stocks 1.0 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst Coverage23andMe has only been the subject of 1 research reports in the past 90 days.Read more about 23andMe's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.48% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 23andMe has recently decreased by 10.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 2.5 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for 23andMe this week, compared to 7 articles on an average week.Search InterestOnly 15 people have searched for ME on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows10 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,528.00 in company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.10% of the stock of 23andMe is held by institutions.Read more about 23andMe's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 23andMe's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About 23andMe Stock (NASDAQ:ME)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesMay 7, 2024 | insidertrades.com23andMe Holding Co. (NASDAQ:ME) Insider Kathy L. Hibbs Sells 38,551 SharesApril 20, 2024 | insidertrades.com23andMe Holding Co. (NASDAQ:ME) Insider Sells $18,117.56 in StockMay 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!May 7, 2024 | msn.comFind your family tree without compromising your dataMay 7, 2024 | yahoo.comThe 23andMe DNA test makes the most thoughtful Mother's Day surprise, and right now it's less than $150 — save 35%May 7, 2024 | yahoo.comThe 23andMe DNA test makes the most thoughtful Mother's Day surprise, and it just dropped to $148 — save 35%May 7, 2024 | msn.com23andMe Helps Ex-Miss Nevada Who Was Abandoned As Baby Find Biological MomMay 1, 2024 | ca.style.yahoo.comAmazon deal: These 23andMe DNA kits are up to $100 off right now — 'results are truly amazing'May 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!April 30, 2024 | businesswire.comPotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseApril 24, 2024 | globenewswire.com23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | fool.comThis Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be NextApril 19, 2024 | finance.yahoo.com23andMe CEO Anne Wojcicki Says She’s Weighing Buyout BidApril 19, 2024 | msn.comOnce Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's FutureApril 18, 2024 | reuters.comColumn: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Ask class members.April 18, 2024 | bizjournals.com23andMe going privateApril 18, 2024 | msn.com23andMe's business is basically worthless. Its CEO now wants to buy it.April 18, 2024 | proactiveinvestors.com23andMe CEO reveals take-private planApril 18, 2024 | investorplace.comME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private DealApril 18, 2024 | investopedia.com23andMe CEO Wojcicki Plans To Take DNA-Testing Firm PrivateApril 18, 2024 | cnbc.com23andMe CEO Anne Wojcicki considers taking company privateApril 18, 2024 | seekingalpha.comWall Street Breakfast Podcast: TikTok Divestment Bill On Potential Fast TrackApril 18, 2024 | msn.com23andMe Holding (ME) Price Target Decreased by 13.33% to 1.26April 18, 2024 | msn.com23andMe CEO Anne Wojcicki eyes taking DNA-testing company privateApril 18, 2024 | finance.yahoo.com23andMe announces CEO’s intention to pursue a potential take-privateApril 18, 2024 | globenewswire.com23andMe announces CEO's intention to pursue a potential take-privateApril 18, 2024 | 247wallst.com23andMe May Disappear as Public StockSee More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/25/2023Today5/08/2024Next Earnings (Estimated)5/23/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees769Year FoundedN/APrice Target and Rating Average Stock Price Target$0.47 High Stock Price Target$0.47 Low Stock Price Target$0.47 Potential Upside/Downside-2.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,660,000.00 Net Margins-210.48% Pretax Margin-210.71% Return on Equity-52.99% Return on Assets-39.32% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.04 Sales & Book Value Annual Sales$299.49 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book0.31Miscellaneous Outstanding Shares482,920,000Free Float349,873,000Market Cap$233.11 million OptionableNot Optionable Beta1.24 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, President & Chair of the BoardMr. Joseph Selsavage (Age 61)Interim CFO & Accounting Officer Comp: $574.56kKey CompetitorsFoghorn TherapeuticsNASDAQ:FHTXVeruNASDAQ:VERUConduit PharmaceuticalsNASDAQ:CDTAC ImmuneNASDAQ:ACIUAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 98,564 shares on 5/7/2024Ownership: 0.024%Wittenberg Investment Management Inc.Bought 893,552 shares on 5/3/2024Ownership: 0.474%Kathy L HibbsSold 38,551 sharesTotal: $18,889.99 ($0.49/share)China Universal Asset Management Co. Ltd.Bought 24,604 shares on 4/29/2024Ownership: 0.013%Kathy L HibbsSold 38,548 sharesTotal: $18,117.56 ($0.47/share)View All Insider TransactionsView All Institutional Transactions ME Stock Analysis - Frequently Asked Questions Should I buy or sell 23andMe stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ME, but not buy additional shares or sell existing shares. View ME analyst ratings or view top-rated stocks. What is 23andMe's stock price target for 2024? 1 brokers have issued twelve-month price targets for 23andMe's stock. Their ME share price targets range from $0.47 to $0.47. On average, they predict the company's share price to reach $0.47 in the next year. This suggests that the stock has a possible downside of 2.6%. View analysts price targets for ME or view top-rated stocks among Wall Street analysts. How have ME shares performed in 2024? 23andMe's stock was trading at $0.9135 at the start of the year. Since then, ME shares have decreased by 47.2% and is now trading at $0.4827. View the best growth stocks for 2024 here. When is 23andMe's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our ME earnings forecast. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings results on Thursday, May, 25th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business earned $92.38 million during the quarter, compared to the consensus estimate of $88.40 million. 23andMe had a negative net margin of 210.48% and a negative trailing twelve-month return on equity of 52.99%. The company's revenue for the quarter was down 8.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) earnings per share. What ETF holds 23andMe's stock? Global X Telemedicine & Digital Health ETF holds 305,477 shares of ME stock, representing 0.32% of its portfolio. Who are 23andMe's major shareholders? 23andMe's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wittenberg Investment Management Inc. (0.47%), Mirador Capital Partners LP (0.07%), SG Americas Securities LLC (0.02%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ME) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.